Product Details
Ebixa® 10 mg Film Tablet Price In Pakistan
Ebixa® 10 mg Film Tablet contains memantine hydrochloride, an anti-dementia medicine. It is used for the treatment of adults with moderate to severe Alzheimer’s disease. Memantine acts on the glutamate/NMDA receptor system in the brain and helps regulate excessive glutamate activity associated with Alzheimer’s disease.
Ebixa treatment should be started and supervised by a doctor experienced in managing Alzheimer’s disease.
Benefits
- Used in the treatment of moderate to severe Alzheimer’s disease.
- Contains memantine hydrochloride as the active ingredient.
- Helps regulate excessive NMDA receptor activity in the brain.
- May help maintain cognitive and functional abilities in suitable patients.
- Film-coated tablet formulation for oral administration.
- Treatment response and tolerability can be regularly assessed by the treating physician.
Specifications
| Specification | Details |
|---|---|
| Brand Name | Ebixa® |
| Active Ingredient | Memantine Hydrochloride |
| Strength | 10 mg |
| Form | Film-Coated Tablet |
| Route | Oral |
| Drug Class | Anti-dementia Medicine / NMDA Receptor Antagonist |
| Main Indication | Moderate to Severe Alzheimer’s Disease |
| Prescription | Prescription Medicine |
| Tablet Description | Pale yellow to yellow, oval-shaped tablet with a breaking line |
| Manufacturer / MAH | H. Lundbeck A/S |
Each Ebixa 10 mg film-coated tablet contains 10 mg memantine hydrochloride, equivalent to 8.31 mg memantine. The tablet can be divided into equal doses.
How To Use
- Take Ebixa exactly as prescribed by your doctor.
- It is generally taken once daily at approximately the same time each day.
- Treatment is normally started at a lower dose and gradually increased to reduce the risk of side effects.
- The standard titration described in the product information increases the dose by 5 mg per week during the first three weeks, with a recommended maintenance dose of 20 mg once daily from week four, when appropriate.
- The 10 mg tablet may be used as part of the dose-titration schedule; it does not necessarily mean that 10 mg is the final daily dose.
- Patients with moderate or severe kidney impairment may require a lower dose.
- Treatment should be regularly reviewed by the doctor to assess benefit and tolerability.
- Do not change the dose or stop treatment without medical advice.
